New hope for acute leukemia patients: Helmholtz Munich researchers, led by Prof. Irmela Jeremias, have identified a promising therapeutic target, ADAM10, which could improve treatment strategies for relapsed leukemia. Their study, recently published…

Prof. Michael Sattler on exploring the impact of understanding molecular disease mechanisms and advancing personalized therapies.

The rise in asthma has been linked to different environmental and lifestyle factors including dietary habits. Researchers at Helmholtz Munich now discovered that a higher salt intake contributes to allergic asthma incidence in females. The team…

An interview with Prof. Markus Diefenbacher, new Principal Investigator (PI) at the Helmholtz Munich Institute for Lung Health and Immunity

The rise of RNA viruses like SARS-CoV-2 highlights the need for new ways to fight them. RNA-targeting tools like CRISPR/Cas13 are powerful but inefficient in the cytoplasm of cells, where many RNA viruses replicate. Scientists from Helmholtz Munich…

An interview with Prof. Fabian Theis, Head of the Computational Health Center, and Prof. Bjoern Eskofier, Group Leader for Translational Digital Health. The researchers hosted the first Munich Health Foundation Model Symposium on April 10, 2024, at…

Prof. Magdalena Götz about the fascinating research on reprogramming glia cells and cell replacement therapy in the field of brain injuries

Epigenetic changes play important roles in cancer, metabolic and aging-related diseases, but also during loss of resilience as they cause the genetic material to be incorrectly interpreted in affected cells. A major study by scientists at Helmholtz…

Prof. Maria-Elena Torres-Padilla about empowering a team and her enthusiasm for epigenetics.

To mechanistically understand the root causes of lung disease, and identify drugs that target specific pathways, the scientists around Prof. Herbert Schiller and Dr. Gerald Burgstaller from Helmholtz Munich are collecting deep molecular insights from…

A groundbreaking study now published in Nature Genetics marks a turning point in depression genetics, offering new hope for personalized medicine through enhanced Polygenic Risk Scores (PRS).

Pediatricians and computer scientists join forces at the Helmholtz Munich Institute for Diabetes Research to identify children with type 1 diabetes before they develop symptoms. With the help of advanced statistics and machine learning, the…

Researchers from Helmholtz Munich have reached a significant milestone in precision medicine with their new publication on the 'Oncology Biomarker Discovery (OncoBird)' framework. This innovative approach aims to systematically identify actionable…

Colorectal cancer (CRC) ranks second in leading causes of cancer-related deaths globally, according to the WHO. For the first time, researchers from Helmholtz Munich and the University of Technology Dresden (TU Dresden) show that artificial…

Prof. Reinhard Zeidler about hope in the fight against glioblastoma, the most common and malignant form of brain tumor and how he accelerates the development of antibodies into application.

Daniel Krappmann about his new Research Unit "Signaling and Translation" at Helmholtz Munich